ReviewThe Journal of infectious diseases2013
Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels.
Review in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.Journal of viral hepatitis · 2019Trial
- Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.The International journal on drug policy · 2015Trial
- From Education to Action-The Impact of Hepatitis C Micro-Elimination Education on Healthcare Provider Confidence and Linkage to Care: A Quasi-Experimental Study.Health science reports · 2025Article
- Perspectives on a transitional housing program for people who use substances who experience homelessness and live with a mental health issue: a pilot study in an urban northern city in Canada.Substance abuse treatment, prevention, and policy · 2025Article
- Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.Canadian liver journal · 2025Article
- Disengagement from Care Among People Co-Infected with HIV and HCV: A Scoping Review.AIDS and behavior · 2024Article
- Article
- Initiation of oral hepatitis C virus treatment: Which barriers are pertinent for ambulatory individuals with a history of illicit substance use? A qualitative interview study.Health science reports · 2024Article
- Hepatitis C virus care cascade among people who inject drugs in puerto rico: Minimal HCV treatment and substantial barriers to HCV care.Drug and alcohol dependence reports · 2023Article
- Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia.Epidemiology and infection · 2023Article
- Barriers and Facilitators to Hepatitis C Virus (HCV) Treatment for Aboriginal and Torres Strait Islander Peoples in Rural South Australia: A Service Providers' Perspective.International journal of environmental research and public health · 2023Article
- Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project.Addiction science & clinical practice · 2022Article
- Barriers and Facilitators of Hepatitis C Care in Persons Coinfected with Human Immunodeficiency Virus.International journal of environmental research and public health · 2022Article
- Optimising community health services in Australia for populations affected by stigmatised infections: What do service users want?Health & social care in the community · 2022Review
- Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learning.BMC medical research methodology · 2022Article
- Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study.Journal of clinical medicine · 2022Article
- Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Viruses · 2022Observational
- HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017.Preventive medicine · 2021Article
- Factors affecting statin uptake among people living with HIV: primary care provider perspectives.BMC family practice · 2021Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy have been observed, but liver-related morbidity rates remain high, given notoriously low uptake of HCV treatment. Advances in HCV therapy will have a limited impact on the burden of HCV-related disease at the population-level unless barriers to HCV education, screening, evaluation, and treatment are addressed and treatment uptake increases. This review will outline barriers to HCV care in HCV/HIV coinfection, with a particular emphasis on persons who inject drugs, proposing strategies to enhance HCV treatment uptake and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.